

**ILCA**

International Liver Cancer Association

# ILCA School of Liver Cancer 2018

Hot Topics in Clinical Management  
of Primary Liver Cancer

**BOLOGNA, MAY 18-19**

[www.ilca-online.org](http://www.ilca-online.org)



ALMA MATER STUDIORUM  
UNIVERSITÀ DI BOLOGNA



# FRIDAY, MAY 18

**09.00** Opening remarks  
*L. Bolondi - Bologna (Italy)*

## SESSION 1

### THE ROLE OF CIRCULATING AND TISSUE BIOMARKERS

**Chair:** *J.C. Nault - Paris (France)*

**09.10** Predicting the development of HCC in liver cirrhosis  
*E. Villa - Modena (Italy)*

**09.30** Circulating MiRNA for the diagnosis and staging of HCC  
*L. Gramantieri - Bologna (Italy)*

**09.50** Discussion

## SESSION 2

### NAFLD AND HCC

**Chair:** *S. Bellentani - Locarno (Switzerland)*

**10.00** Risk of cirrhosis and HCC in NAFLD: can be predicted and/or quantified?  
*J.F. Dufour - Bern (Switzerland)*

**10.20** Genetic factors associated with HCC in NASH  
*L. Valenti - Milan (Italy)*

**10.40** Recommendations for screening or surveillance for NAFLD  
*E. Bugianesi - Turin (Italy)*

**11.15** *Coffee break*

# FRIDAY, MAY 18

## SESSION 3 DIAGNOSTIC DILEMMAS

**Chairs:** *R. Golfieri - Bologna (Italy), F. Trevisani - Bologna (Italy)*

- 11.30** Time for new parameters in MRI for the diagnosis of HCC?  
*R. Golfieri - Bologna (Italy)*
- 11.50** LI RADS classification system, the issue of cholangiocarcinoma  
*F. Piscaglia - Bologna (Italy)*
- 12.10** Discussion
- 12.20** **Round table debate starting from clinical cases**  
Management of undefined small nodular liver lesion in cirrhosis  
**Chair:** *L. Bolondi - Bologna (Italy)*  
**Discussants:** *M. Cescon - Bologna (Italy), J.F. Dufour - Bern (Switzerland)*  
*F. Piscaglia - Bologna (Italy), M. Renzulli - Bologna (Italy)*

**13.00** *Lunch*

## SESSION 4 ANTIVIRAL TREATMENT AND HCC

**Chairs:** *P. Andreone - Bologna (Italy), J. Bruix - Barcelona (Spain)*

- 14.00** Treatment of HBV with antivirals and influence on the risk of HCC  
*P. Lampertico - Milan (Italy)*
- 14.20** Risk of development and natural history of HCC arisen in HCV patient with SVR after interferon based treatment  
*S. Bhoori - Milan (Italy)*
- 14.40** Treatment of chronic hepatitis C with IFN-free DAA regimens and risk of HCC  
*M. Colombo - Milan (Italy)*
- 15.00** Strategies for treatment of HCV with DAA after curative HCC treatment
- I do always treat  
*V. Calvaruso - Palermo (Italy)*
- I do not treat  
*M. Reig - Barcelona (Spain)*
- Sometimes I treat  
*P.R. Galle - Mainz (Germany)*
- 15.45** Discussion
- 16.00** *Coffee break*

# FRIDAY, MAY 18

## SESSION 5

### CHALLENGES IN CURRENT SYSTEMIC THERAPY FOR HCC

**Chairs:** *P.J. Johnson - Liverpool (United Kingdom), L. Rimassa - Milan (Italy)*

**16.20** Is it possible to compare the multiple treatments tested for HCC?

The Network Metanalysis model

*A. Cucchetti - Bologna (Italy)*

**16.40** Is efficacy of Sorafenib and Regorafenib predictable?

*M. Reig - Barcelona (Spain)*

**17.00** Stopping rules for Sorafenib in the era of Regorafenib

*P.J. Johnson - Liverpool (United Kingdom)*

**17.20** Treatment of HCC in Child-Pugh B class

*F. Trevisani - Bologna (Italy)*

**17.40** Discussion

**18.00 Round table debate**

Management of advanced HCC in patients with comorbidities

Case presentations

*F. Tovoli - Bologna (Italy)*

Expert discussants

*B. Daniele - Benevento (Italy), M. Reig - Barcelona (Spain), F. Trevisani - Bologna (Italy)*

**18.30** Closure of the day

# SATURDAY, MAY 19

## SESSION 6

### A LOOK INTO THE FUTURE OF HCC

**Chairs:** *L. Bolondi - Bologna (Italy), J.F. Dufour - Bern (Switzerland)*

- 08.30** The role of Radioembolization  
*M. Seidensticker - München (Germany)*
- 08.50** New molecular targets for systemic therapy  
*J.C. Nault - Paris (France)*
- 09.10** Background and clinical perspectives of immune check-point inhibitors  
*P.R. Galle - Mainz (Germany)*
- 09.30** Postprogression survival and design of second or third line trials in 2018  
*J. Bruix - Barcelona (Spain)*
- 09.50** Recently concluded and ongoing trials for systemic therapy checkpoint of HCC in 2018: current standpoint  
*L. Bolondi - Bologna (Italy)*
- 10.10** Discussion
- 10.30** *Coffee break*

## SESSION 7

### THE EMERGING ISSUE OF CHOLANGIOCARCINOMA

**Chairs:** *P.J. Johnson - Liverpool (United Kingdom), F. Piscaglia - Bologna (Italy)*

- 10.50** Development of HCC and ICC.  
Molecular pathways with a perspective of clinical relevance  
*J.C. Nault - Paris (France)*
- 11.10** Indications for surgery  
*M. Cescon - Bologna (Italy)*
- 11.50** Treatment of mass-forming non surgical intrahepatic cholangiocarcinoma  
*L. Rimassa - Milan (Italy)*
- 12.10** Locoregional treatment of non surgical obstructive cholangiocarcinoma of the main bile ducts  
*R. Golfieri - Bologna (Italy)*
- 12.30** Discussion
- 12.50** Closure of the meeting

# GENERAL INFORMATION

## MEETING VENUE

Aula Magna Nuove Patologie - Pad. 5

S. Orsola Malpighi Hospital - Via Massarenti, 9 - 40125 Bologna (Italy)

The venue is located 10 minutes from Bologna's city centre.

It can easily be reached by means of public transportation system.

## AIRPORT

The airport is located 10 km from the city centre. The transfer from the airport to the venue and most of the hotels takes around 30 min by taxi and costs around €20; you can also use the airport bus to get to the centre of the town.

## C.M.E. CREDITS

Through the C.M.E. division of the Ministry of Health, this meeting has been registered as part of the Italian credit system for medical studies. Credit certificates shall be issued only if the participant has successfully attended the whole meeting and his/her professional qualifications meet the requirements for entitlement to the study credits in question. The C.M.E. credit certificate will be issued only after the candidate has completed and returned the assessment questionnaire at the end of the meeting.

## LANGUAGE

The official language of the meeting is English. Simultaneous translation will not be provided.

## LIABILITY AND INSURANCE

The organiser is not able to take any responsibility whatsoever for injury or damage involving persons and property during the meeting. Participants are advised to take out their own personal travel and health insurance for their trip.

## MEETING DOCUMENTS AND BADGES

The meeting documents should be collected on-site at the registration desk at the venue.

Name badges must be worn at all time during the meeting.

## CERTIFICATE OF ATTENDANCE

The certificate of attendance will be collected from the registration desk during the last day of the meeting.

## COFFEE BREAKS AND LUNCHES

Coffee breaks and lunches are included in the registration fee.

## ACKNOWLEDGEMENT

The ILCA School of Liver Cancer 2018 is an initiative organised thanks to an unrestricted educational grant from Bayer HealthCare.



ILCA is also grateful to the following scientific publications for their support

**EMJ** EUROPEAN  
MEDICAL JOURNAL • **Liver  
Cancer**



## **SCIENTIFIC DIRECTORS**

**Prof. Luigi Bolondi, Prof. Fabio Piscaglia**

Unit of Internal Medicine

Department of Medical and Surgical Sciences

University of Bologna - Alma Mater Studiorum

S. Orsola Malpighi Hospital

Via Albertoni, 15 - 40125 Bologna (Italy)

luigi.bolondi@unibo.it - fabio.piscaglia@unibo.it

## **ORGANISING SECRETARIAT**

**International Liver Cancer Association (ILCA)**

Boulevard du souverain, 280 - B-1160 Brussels (Belgium)

Tel: +32 2 7892345 - Fax: +32 2 7431550

info@ilca-online.org - www.ilca-online.org

## **LOCAL SECRETARIAT**

**FC EVENTI S.R.L.**

Vicolo Posterla, 20/2a - 40125 Bologna (Italy)

Tel: +39 051 236895 - Fax: +39 051 2916933

info@fc-eventi.com - www.fc-eventi.com